SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Alpha7 nicotinic acetylcholine receptors (n-AChRs) are implicated in cognitive function and neurological disorders.
• Selective modulation of alpha7 n-AChRs represents a promising therapeutic strategy.

Purpose of the Study:

• To characterize the pharmacological and functional profile of SSR180711, a novel selective alpha7 n-AChRs partial agonist.
• To evaluate the effects of SSR180711 on neurotransmission and synaptic plasticity in the hippocampus.

Main Methods:

• In vitro binding assays and functional studies using expressed human alpha7 n-AChRs.
• Electrophysiological recordings (EPSCs, IPSCs) in cultured neurons and brain slices.
• In vivo microdialysis and electrophysiological recordings in anesthetized and freely moving rodents.

Main Results:

• SSR180711 demonstrated high affinity and selectivity for alpha7 n-AChRs, with partial agonist activity.
• The compound penetrated the brain and modulated glutamatergic and GABAergic neurotransmission.
• SSR180711 enhanced long-term potentiation (LTP) and increased acetylcholine release in the hippocampus and prefrontal cortex.

Conclusions:

• SSR180711 is a selective alpha7 n-AChRs partial agonist with significant effects on neurotransmission and synaptic plasticity.
• These findings support the potential of SSR180711 as a therapeutic agent for conditions involving alpha7 n-AChRs dysfunction.